ITT Exelis Awarded an Order Valued at $56 Million (XLS, LH)
Contact Information
Jhonny
Bestotc
5440 W. Sahara Ave., Suite 205
Las Vegas NV, 89146

702 448 1543

[Sequella Inc., licensed its B-SMART™ technology to LabCorp to allow LabCorp to develop a new laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis and to commercially use the assay in the United States]

Online PR News – 23-October-2012 –ITT Exelis (NYSE: XLS) XLS ("ITT Exelis") has been awarded an order from the U.S. Army valued at $56 million to provide power amplifiers and vehicular adapters for use with existing radios operated by the U.S. Army and the National Guard. Exelis has developed, manufactured and supported six generations of continually improved SINCGARS radios since the first radio was delivered in 1988. Since then, the company has delivered enhancements in functionality and software while reducing size, weight and power requirements, enabling SINCGARS to meet emerging battlefield demands. ITT Exelis (NYSE: XLS) is a diversified, top-tier global aerospace, defense and information solutions company with strong positions in enduring and emerging global markets. Exelis is a leader in networked communications, sensing and surveillance, electronic warfare, navigation, air traffic solutions and information systems with growing positions in cyber security, composite aerostructures, logistics and technical services. The company has a 50-year legacy of innovation and technology expertise, partnering with customers worldwide to deliver affordable, mission-critical products and services for managing global threats, conflicts and complexities. Headquartered in McLean, Va., the company employs about 20,500 people and generated 2011 sales of $5.8 billion. www.exelisinc.com

Laboratory Corporation of America Holdings (NYSE: LH) Sequella Inc., licensed its B-SMART™ technology to LH ("LabCorp") to allow LabCorp to develop a new laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis and to commercially use the assay in the United States. The assays that LabCorp will develop using B-SMART™ technology will combine nucleic acid testing with phage-based technology to accurately and quickly identify any resistance of M. tuberculosis clinical isolates to antitubercular antibiotics, regardless of whether the resistance genotype is known. Financial terms of the agreement were not disclosed. Sequella retains all rights to commercialize B-SMART™ technology worldwide for indications other than tuberculosis, and for territories other than the United States for tuberculosis. Nucleic acid-based diagnostics are well established in laboratory medicine, and many are used to screen for infectious diseases, resulting in a $1.1 billion industry in the United States. The B-SMART™ technology is compatible with any nucleic acid detection system, can be used to develop tests that detect resistance to any drug, and can provide results in hours. Laboratory Corporation of America® Holdings ("LabCorp") (NYSE: LH), an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine Sciences. LabCorp conducts clinical trials testing through its LabCorp Clinical Trials division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.

Crown Equity Holdings Inc. (CRWE) As a publishing company, CRWE has been evolving in a worldwide online multimedia advertising publisher. CRWE is paving the way in how we communicate worldwide. From buying and selling goods to how people receive news. The company's focus is on the distribution of current information to a target audience which advertisers want to reach. The Company continues to diversify and the Crown Equity family continues to expand. Crown Equity Holdings family consist of CRWE Press Release (crwepressrelease.com), CRWE Direct (www.crwedirect.com) , CRWE AD Services (www.crwe-adservices.com), CRWE Tube (www.crwetube.com), CRWE Newswire (www.crwenewswire.com), CRWE Domains (www.crwedomains.com), and CRWE Real Estate (www.crwerealestate.com). CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com.

To view recent article please visit http://crweselect.com/30974/stock-alerts/unifirst-4q-revenue-3124-million-up-74-unf-svu/

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://crweselect.com/disclaimer).

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
Copyright 2014 Online PR Media | PO Box 5043 | La Quinta, CA 92248